摘要
目的探讨血清肿瘤标志物CYFRA21-1检测原发性肝癌(primary hepatic cancer,PHC)的诊断价值。方法2003年7月至2007年12月收治的330例肝病患者,其中组织病理学诊断为原发性肝癌者192例,非原发性肝癌者138例。采用电化学发光免疫分析法对330例肝病患者的血清CYFRA21-1水平进行检测。结果血清CYFRA21-1水平PHC组为(9.73±1.02)ng/mL,非PHC患者为(1.33±0.26)ng/mL,两组间差异具有统计学意义(P<0.01),不同组织学分型的PHC患者血清CYFRA21-1水平之间的差异也具有统计学意义(P<0.01)。结论检测血清中CYFRA21-1水平对HPC的诊断有一定的指导意义。
Objective To explore the value of using CYFRA21-1 in the early diagnosis of primary hepatic cancer. Methods Serum levels of CYFRA21-1 from 192 patients with primary hepatic cancer and 138 patients with non-HPC cases admitted to our hospital from July 2003 to December 2007 were measured and analyzed. The level of AFU was detected with ECLIA. Results The level of serum CYFRA21-1 in PHC group （9.73 ± 1.02） ng/mL was significantly different from the non-PHC group （ 1.33 ± 0.26） ng/mL （P〈0.01）. Differences in the level of CYFRA21-1 were also observed in HPC group with various historical types. Conclusion The level of CYFRA21-1 may be used in the early diagnosis of primary hepatic cancer.
出处
《热带医学杂志》
CAS
2009年第3期275-276,287,共3页
Journal of Tropical Medicine
基金
广州市卫生局资助项目(No.2007-YB-117)。
